Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial-Reference-Cited by-同舟云学术

Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

Published:2012-10 Issue: Volume:107 Page:S609-S610
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:American Journal of Gastroenterology

Author:

Feagan Brian,Rutgeerts Paul,Sands Bruce,Sandborn William,Colombel Jean-Frederic,Hanauer Stephen,Van Assche Gert,Axler Jeffrey,Kim Hyo-Jong,Danese Silvio,Fox Irving,Milch Catherine,Sankoh Serap,Wyant Tim,Xu Jing,Parikh Asit

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study;European Journal of Pediatrics;2021-04-20

2. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis;Cochrane Database of Systematic Reviews;2017-09-08

3. Vedolizumab in der Behandlung der Colitis ulcerosa und des Morbus Crohn – ein Konsensus der Arbeitsgruppe „Chronisch Entzündliche Darmerkrankungen“ der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie;Zeitschrift für Gastroenterologie;2016-03-16

4. Vedolizumab for induction and maintenance of remission in ulcerative colitis;Cochrane Database of Systematic Reviews;2014-08-08

5. Biological Agents for Moderately to Severely Active Ulcerative Colitis;Annals of Internal Medicine;2014-05-20